Louise Chen
Stock Analyst at Scotiabank
(2.69)
# 790
Out of 5,182 analysts
294
Total ratings
47.33%
Success rate
3.08%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Sector Outperform | $35 → $40 | $34.95 | +14.45% | 5 | Jan 29, 2026 | |
| JNJ Johnson & Johnson | Maintains: Sector Outperform | $230 → $265 | $227.19 | +16.64% | 41 | Jan 22, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Sector Perform | $53 → $60 | $58.22 | +3.06% | 2 | Jan 9, 2026 | |
| MRK Merck & Co. | Maintains: Sector Outperform | $105 → $120 | $112.16 | +6.99% | 26 | Dec 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $701.42 | +9.78% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $21.49 | +272.27% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $4.41 | +104.08% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $30.61 | -54.26% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.88 | +538.30% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $23.11 | +137.99% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Perform | $55 | $65.15 | -15.58% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $3.85 | +289.61% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $126.84 | -60.58% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $6.88 | +118.02% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $36.63 | -53.59% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $13.43 | +421.22% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $17.39 | +187.52% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $8.56 | +250.47% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $21.54 | +155.34% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.48 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $43.88 | +264.63% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $56.93 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $206.60 | +16.17% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $26.33 | +70.91% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.07 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $27.83 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $963.33 | -8.13% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.33 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $27.12 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.74 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.33 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.50 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.07 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.98 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.99 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.56 | +1,725.84% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.47 | +102.43% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $13.30 | +275.94% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $23.35 | +114.13% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.07 | +141.55% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.64 | +1,303.62% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $6.69 | +25,224,115.25% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $227.58 | +13.37% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.27 | +3,837.01% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.10 | +1,718.18% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $5.20 | +765.38% | 1 | Jun 22, 2017 |
Teva Pharmaceutical Industries
Jan 29, 2026
Maintains: Sector Outperform
Price Target: $35 → $40
Current: $34.95
Upside: +14.45%
Johnson & Johnson
Jan 22, 2026
Maintains: Sector Outperform
Price Target: $230 → $265
Current: $227.19
Upside: +16.64%
Bristol-Myers Squibb Company
Jan 9, 2026
Maintains: Sector Perform
Price Target: $53 → $60
Current: $58.22
Upside: +3.06%
Merck & Co.
Dec 4, 2025
Maintains: Sector Outperform
Price Target: $105 → $120
Current: $112.16
Upside: +6.99%
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $701.42
Upside: +9.78%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $21.49
Upside: +272.27%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $4.41
Upside: +104.08%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $30.61
Upside: -54.26%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.88
Upside: +538.30%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $23.11
Upside: +137.99%
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $65.15
Upside: -15.58%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $3.85
Upside: +289.61%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $126.84
Upside: -60.58%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $6.88
Upside: +118.02%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $36.63
Upside: -53.59%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $13.43
Upside: +421.22%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $17.39
Upside: +187.52%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $8.56
Upside: +250.47%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $21.54
Upside: +155.34%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.48
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $43.88
Upside: +264.63%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $56.93
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $206.60
Upside: +16.17%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $26.33
Upside: +70.91%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.07
Upside: -
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $27.83
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $963.33
Upside: -8.13%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.33
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $27.12
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.74
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.33
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.50
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.07
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.98
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.99
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.56
Upside: +1,725.84%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.47
Upside: +102.43%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $13.30
Upside: +275.94%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $23.35
Upside: +114.13%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $2.07
Upside: +141.55%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.64
Upside: +1,303.62%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $6.69
Upside: +25,224,115.25%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $227.58
Upside: +13.37%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.27
Upside: +3,837.01%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.10
Upside: +1,718.18%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $5.20
Upside: +765.38%